CLV Shares Clover Corporation Limited
ASX · ASXLast in our picks 2026-10-23 — not in the current list; analysis below is from that screen
Rare-disease franchise expansion offers earnings growth despite product concentration risk.
Future value: $1.32 (+29.56%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Expansion into women’s health supports prescription growth.
- ▸Above 50-day MA (+6.34%)
- ▸Above 200-day MA — long-term uptrend
- ▸Volume 1.76× average — accumulation
- ▸~30% upside to price target
Is CLV a buy right now?
Trend: CLV is trading above the 50-day average (+3.65%), RSI 50 — neutral momentum, with a 3-month return of +5.29%.
Valuation & quality: Clover Corporation Limited trades on a trailing P/E of 16.6, forward P/E 10.3, PEG 2.86, price-to-book 2.12; fundamentals show net margin 10.7%, return on equity 13.9%, revenue growth 10.2% year on year.
Analyst consensus: 2 analysts have a mean 12-month price target of A$1.31 (+32.2% vs the last close; range A$1.17 – A$1.46), consensus rating “none”.
Income: trailing dividend yield 2.46%.
Our screen: STRONG BUY (score 5) — Rare-disease franchise expansion offers earnings growth despite product concentration risk.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +35.90% | -7.50% | -8.20% | -5.60% | +12.90% | -4.20% | +13.00% | -3.80% |
Fundamentals
Analyst price target
Technical signals
About Clover Corporation Limited
Clover Corporation Limited engages in the production, refining, and sale of natural oils and encapsulated powders in Australia, New Zealand, Asia, Europe, the Middle East, and the Americas.
Sector: Consumer Defensive · Industry: Packaged Foods · Australia · 81 employees · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.